Intercept Pharmaceuticals Inc. (ICPT)

95.72 -3.73 (-3.751%)

IEX Real-Time Price

October 19, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 99.45

Price Open 99.9

Volume: 669,294

Avg Volume: 454,691

Market Cap: 2.83B

P/E Ratio -7.3

52 Wk Range 51.05-133.74



ICPT Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-09-28
28.64M
3.33M
8.99
11.62%

2018-09-14
28.64M
3.68M
11.18
12.84%

2018-08-31
28.64M
3.78M
6.70
13.21%

2018-08-15
28.64M
4M
6.00
13.98%




ICPT Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-02
Q2 2018
BTO
-2.83 (8)
-2.58
0.25

2018-05-08
Q1 2018
BTO
-3.41 (8)
-3.22
0.19

2018-05-03
Q1 2018
N/A
-3.42 (8)
0.00
0.00

2018-02-22
Q4 2017
N/A
-3.39 (10)
-4.43
-0.86

News

Expected Value Investing:  Analyzing Genfit's Huge Potential (2018-10-19 08:00 SeekingAlpha)

In this article, I'd like to continue my recent focus on some of the major players in the NASH drug development race. Genfit (OTCPK: GNFTF ), a France-based biotech, is one of the firms farthest along in the development process - it is currently in process of conducting a Phase 3 trial to eva…

 


Statistics

Shares Outstanding: 29.56M

Top 15 Institution Percent: 94.60

Price To Sales: 25.08

Price To Book: 20.06

Revenue: 79.02M

Gross Profit: 78.03M

Cash: 907.67M

Debt: N/A

Return On Assets: -55.82

Return On Equity: -215.41

Profit Margin: N/A

Price History

Beta: -1.22

50-day Moving Avg: 111.66

200-day Moving Avg: 82.23

YTD Change: 69.87

5-day Change: -5.72

1-month Change: -20.63

3-month Change: N/A

6-month Change: 32.98

1-year Change: 43.87

Revenue Per Share: 3.00

Revenue Per Employee: 155860.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Intercept Pharmaceuticals Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need.